CNP analogue

Vosoritide clinical trials

Answer

Vosoritide has 23 registered trials: 12 running, 4 completed, 0 stopped early. 3 posted results.

Trial registerClinicalTrials.gov and EU CTIS, read 2026-10-03

TrialTitleStatusPhaseRegisteredResults
NCT07441876
Trial register
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasiacurrently recruiting participants-2026-03-02-
NCT06668805
Trial register
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatmentrunning, but no longer enrolling-2024-10-31-
2024-512261-14-00
Trial register
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Not stated2--
NCT07073014
Trial register
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasiaenrolling by invitation only-2025-07-18-
2024-520137-74-00
Trial register
A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short StatureNot stated2--
2024-517238-16-00
Trial register
A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with HypochondroplasiaNot stated3--
2024-515861-33-00
Trial register
A Phase 2, Randomized, Multicenter, Study of Vosoritide in Children with Noonan Syndrome with Inadequate Growth During or After Human Growth Hormone TreatmentNot stated2--
NCT06382155
Trial register
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Staturecurrently recruiting participants-2024-04-24-
2024-513129-22-00
Trial register
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with HypochondroplasiaNot stated3--
2025-523811-12-00
Trial register
A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with AchondroplasNot stated2/3--
NCT07126262
Trial register
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Monthscurrently recruiting participants-2025-08-17-
NCT04219007
Trial register
Vosoritide for Selected Genetic Causes of Short Staturerunning, but no longer enrolling-2020-01-06-
NCT02724228
Trial register
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)running, but no longer enrolling-2016-02-12-
NCT03424018
Trial register
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasiarunning, but no longer enrolling-2017-12-28-
NCT03989947
Trial register
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasiarunning, but no longer enrolling-2019-05-22-
NCT04554940
Trial register
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasiarunning, but no longer enrolling-2020-09-18-
NCT05845749
Trial register
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VIrunning, but no longer enrolling-2023-05-06-
NCT06455059
Trial register
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasiarunning, but no longer enrolling-2024-06-12-
NCT05849389
Trial register
Vosoritide for Short Stature in Turner Syndromelast verified some time ago; the register no longer confirms its status-2023-05-08-
NCT03583697
Trial register
A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasiacompleted-2018-06-14Posted
NCT03197766
Trial register
A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasiacompleted-2017-05-23Posted
NCT02055157
Trial register
A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasiacompleted-2013-04-18Posted
NCT01590446
Trial register
A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteerscompleted-2012-03-14-

Source: ClinicalTrials.gov and EU CTIS, read 2026-10-03. Not medical advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.